Patients enrolled in Prolastin Direct experienced 10% fewer exacerbations.1Exacerbation Reduction Graph

Prolastin Direct Alpha-1 health management program helps improve patient outcomes.

  • Total exacerbation rate decreased (P<0.001)
  • Unscheduled physician visits decreased (P=0.03)
  • Emergency room visits decreased (P=0.02)

Learn more about Alpha-1 Disease Management and Prevention Program (ADMAPP).

PROLASTIN-C Therapy - You get more than just a product.

Demonstrated efficacy

  • Since 1988 Prolastin has been shown to raise AAT levels in as little as 1 month1.
  • In clinical trials, PROLASTIN-C was as effective as PROLASTIN at raising AAT levels1.

In clinical trials

The most common drug-related adverse reaction observed at a rate of > 5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

The effect of augmentation therapy with any alpha1-proteinase inhibitor (Alpha-1-PI) on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.

Higher purity

Each dose of Prolastin-C delivers ≥90% pure alpha-1 protein allowing it to be more concentrated than Prolastin

Patient conveniences

  • Shorter infusion volume and time compared to PROLASTIN
  • average 15-minute infusion time when given at the recommended infusion rate
  • Easy product storage
  • no refrigeration needed

PROLASTIN DIRECT Alpha-1 health management program helps improve patient outcomes.1

Patients benefit when alpha-1 health management is added to therapy.

Direct Process Flow

Enroll your Alphas in Prolastin Direct Patient Services® now

Enrolling your patients is simple, fill out the prescription and enrollment form.

next: Dosage & Administration of PROLASTIN-C >

Important Safety Information

PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to risk of hypersensitivity.

Hypersensitivity reactions may occur. Should evidence of hypersensitivity reaction be observed, promptly stop infusion and begin appropriate therapy.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. PROLASTIN-C is contraindicated in patients with antibodies against IgA.

The most common drug-related adverse reaction observed at a rate of > 5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Please see accompanying PROLASTIN-C full Prescribing Information for complete prescribing details.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

References
  1. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.
  2. PROLASTIN-C [package insert]. Grifols.